PolyMedix’s CEO to Present at Rodman & Renshaw’s Tenth Annual Global Healthcare Conference on November 10, 2008

Radnor, PA (November 7, 2008) - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will present at Rodman & Renshaw’s Tenth Annual Global Healthcare Conference taking place November 10-12, 2008, at the New York Palace Hotel. Nicholas Landekic, President & C.E.O. of PolyMedix, will give the Company presentation on Monday, November 10 at 5:45 PM (EST) in the Louis Room.

Read More

POLYMEDIX TO MAKE MULTIPLE PRESENTATIONS OF NEW ANTIBIOTIC DATA AT THE 48th ANNUAL INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (ICAAC)

Annual Meeting on Behalf of the American Society of Microbiology (ASM) Being Held In Washington D.C., October 25 - 28, 2008

Data to be presented include new data for PolyMedix antibiotic compounds that have demonstrated antimalarial activity and antifungal activity, as well as in vitro and in vivo Staphylococci data on PolyMedix’s Phase I i.v. antibiotic product candidate, PMX-30063

Radnor, PA (October 28, 2008) -PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will make a total of four presentations of pre-clinical data on its antibiotic compounds at the Interscience Conference on Antimicrobial Agents and Chemotherapy. The conference, held on behalf of the American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA), is taking place in Washington D.C. Saturday, October 25 through Tuesday, October 28, 2008.

Read More

PolyMedix Presents Data on Anti-Tuberculosis Activity of its Novel Antibiotic Compounds

New Directions In AIDS Treatment Research Policy and Care Symposium
Held September 26, 2008, in New York City

Radnor, PA (September 29, 2008) - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, presented new data at the “New Directions in AIDS Treatment Research Policy and Care Symposium” in New York on September 26th, 2008. Pre-clinical in vitro data describing the activity of a variety of PolyMedix’s novel small molecule defensin mimetic antibiotic compounds against Mycobacterium tuberculosis, the bacteria which causes tuberculosis, were presented.

Read More

PolyMedix Closes $4.25 Million Private Placement Financing

Financing Follows $15 Million Public Offering Completed in July 2008

Radnor, PA (September 24, 2008) – PolyMedix Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced today that it has completed a $4.25 million private placement of preferred stock units. Each unit was priced at $7.00 and consisted of one share of PolyMedix convertible preferred stock and a five year warrant initially exercisable for one share of PolyMedix convertible preferred stock at $10.00 per share. Emerging Growth Equities Ltd. of King of Prussia, PA was the placement agent and Carter Securities of New York acted as a selected dealer in the private placement.

Read More

PolyMedix Initiates Dosing in Phase I Clinical Study of Novel Anticoagulant Antagonist Compound

PMX-60056 Heptagonist Is The Only Reversing Agent for Heparin and Low Molecular Weight Heparins in Clinical Development

PMX-60056 is the Company’s Second Clinical Trial Initiation in the Past Month

Radnor, PA (September 23, 2008) - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a Phase I clinical study in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA). PMX-60056 represents an entirely new class of drug, which PolyMedix calls a heptagonist, and is the only reversing agent for heparin and the Low Molecular Weight Heparins (LMWH) in clinical development.

Read More

PolyMedix Initiates Dosing in Phase I Clinical Study of Novel Systemic Antibiotic Compound

PMX-30063 The First and Only Defensin Mimetic Systemic Antibiotic Drug In Human Clinical Trials

PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a Phase I clinical study in Canada for its defensin mimetic antibiotic compound, PMX-30063. PolyMedix received a notice of no objection from Health Canada for the Company’s Clinical Trial Application (“CTA”) for PMX-30063 in May 2008. PMX-30063 is the first and only defensin mimetic antibiotic compound to enter human clinical trials for systemic use, and represents an entirely new class of antibiotic drugs.

Read More

PolyMedix Has Regulatory Clearance to Initiate Phase I Clinical Study of Novel Anticoagulant Antagonist Compound

PMX-60056 Heptagonist The Only Reversing Agent for Heparin and Low Molecular Weight Heparins in Development
PMX-60056 Milestone the Company’s Second Regulatory Clearance in Three Months

Radnor, PA (August 12, 2008) - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has clearance to start human clinical trials in the United States with its anticoagulant reversing agent PMX-60056 under the Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA). PMX-60056 represents an entirely new class of drug, which PolyMedix calls a heptagonist, and is the only reversing agent for heparin and the Low Molecular Weight Heparins (LMWH) in clinical development.

Read More

PolyMedix Closes $15 Million Registered Equity Financing

Funds To Be Used To Advance First Two Drug Candidates Into Human Clinical Trials and Phase IB Testing

Read More

PolyMedix Appoints Two New Directors - Dr. Richard Bank and Dr. Stefan Loren Join the Board of Directors

PolyMedix Inc., has elected Dr. Richard Bank and Dr. Stefan Loren to the Board of Directors.

Read More

PolyMedix Receives Regulatory Clearance to Initiate Phase I Clinical Study of Novel Systemic Antibiotic Compound

PMX-30063 The First Defensin Mimetic Systemic Antibiotic Drug Cleared For Human Clinical Trials

PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, has received a notice of no objection from Health Canada for the Company’s Clinical Trial Application (“CTA”) for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.

Read More

DR. WILLIAM DEGRADO HONORED WITH THE RALPH F. HIRSCHMANN AWARD IN PEPTIDE CHEMISTRY

Dr. William DeGrado, the scientific founder of PolyMedix, Inc. (OTC BB: PYMX), was named the 2008 recipient of the prestigious Ralph F. Hirschmann Award in Peptide Chemistry. The award recognizes a person who has made outstanding contributions in the chemistry, biochemistry, or biophysics of peptides.

Read More

Data on PolyMedix Antimicrobial Polymers presented at American Society of Microbiology 6th Annual Biodefense and Emerging Diseases Research Meeting

PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechcompany developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced that Dr. Byron Brehm-Stecher presented data yesterday at the “American Society of Microbiology 6th Annual Biodefense and Emerging Diseases Research Meeting” in Baltimore relating to PolyMedix’s proprietary antimicrobial compounds.

Read More

PolyMedix Appoints Brian Anderson to Board of Directors

PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, has appointed Brian Anderson to its Board of Directors. Brian Anderson brings over thirty years of experience in the pharmaceutical and biotechnology industries to PolyMedix. Educated at the University of Manitoba, Brian commenced his career in the ...

Read More